Referral for “Neoadjuvant Chemotherapy” for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes

References

• Key Statistics for Bladder Cancer. Available from: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Accessed 721, 2018.
   Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. EAU Guidelines on Muscle-invasive and metastatic bladder cancer 2020. Available from: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic. Accessed 722, 2021.
   Google Scholar
• Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A. Hellenic Genito-Urinary Cancer Group (HCUCG). Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Crit Rev Oncol Hematol. 2015;93(1):36–49.25205597
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866.12944571
   PubMed Web of Science ®Google Scholar
• International Collaboration of trialists. Neoadjuvant methotrexate, vinblastine, and cisplatin chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet. 1999;354:533–540.10470696
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. On behalf of the ESMO guidelines working Group. Bladder cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii40–iii48.25096609
   PubMed Web of Science ®Google Scholar
• Zaid HB, Patel SG, Stimson CJ, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014;83:75–80.24231210
   PubMed Web of Science ®Google Scholar
• Reardon ZD, Patel SG, Zaid HB, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015;67:165–170.24472710
   PubMed Web of Science ®Google Scholar
• Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol. 2012;61:1070–1071.22336379
   PubMed Web of Science ®Google Scholar
• Hanna N, Trinh QD, Seisen T, et al. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA. Eur Urol Oncol. 2018;1:83–90.31100232
   PubMed Web of Science ®Google Scholar
• Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy (New York). 2015;119(4):464–474.
   PubMed Web of Science ®Google Scholar
• Scarberry K, Ponsky L, Cherullo E, et al. Evaluating the impact of the genitourinary multidisciplinary tumour board: should every cancer patient be discussed as standard of care? Can Urol Assoc J. 2018;12(9):E403–8.
   PubMed Web of Science ®Google Scholar
• Harshman LC, Tripathi A, Kaag M, et al. Contemporary patterns of multidisciplinary care in patients with muscle-invasive bladder cancer. Clin Genitourin Cancer. 2018;16(3):213–218.29289519
   PubMed Web of Science ®Google Scholar
• Kinnear N, Smith R, Hennessey DB, Bolton D, Sengupta S. Implementation rates of uro-oncology multidisciplinary meeting decisions. BJU Int. 2017;120(Supplement 3):15–20.28719043
   PubMed Web of Science ®Google Scholar
• Gronostaj K, Czech AK, Fronczek J, et al. Changes in neoadjuvant chemotherapy utilization in muscle invasive bladder cancer treatment: a tertiary center retrospective study. Cent European J Urol. 2020;73:13–18.
   PubMed Web of Science ®Google Scholar
• Nuhn P, May M, Fritsche HM, et al. External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. EJSO. 2012;38:637–642.22459902
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Khan MM, Lerner SP, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011;185(2):456–461.21167527
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017:765–774.
   Google Scholar
• Ho PL, Willis DL, Patil J, et al. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center Experience. Urol Oncol. 2016;34:59.e1–8.
   Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.15273542
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–1489.9809728
   PubMed Web of Science ®Google Scholar
• Martini A, Jia R, Ferket BS, et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer. 2019;125(18):3155–3163.31150110
   PubMed Web of Science ®Google Scholar
• Bamias Α, Dafni U, Karadimou A, et al. Prospective, randomized Phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. Ann Oncol. 2013;24(4):1011–1017.23136231
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Rad Oncol Biol Phys. 2010;76:S3–S9.
   PubMed Web of Science ®Google Scholar
• Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol. 2017;35:2299–2305.28410011
   PubMed Web of Science ®Google Scholar
• Rouanne M, Bajorin DF, Hannan R, et al. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. Eur Urol Oncol. 2020;3(6):728–738.33177001
   PubMed Web of Science ®Google Scholar
• Iyer G, Balar AV, Milowsky MI, et al. Multicenter prospective Phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol. 2018;36:1949–1956.29742009
   PubMed Web of Science ®Google Scholar
• Anari F, O’Neill J, Choi W, et al. Neoadjuvant dose-dense gemcitabine and cisplatin in muscle-invasive bladder cancer: results of a Phase 2 trial. Eur Urol Oncol. 2018;1:54–60.30420974
   PubMed Web of Science ®Google Scholar
• Blick C, Hall P, Pwint T, et al. Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer. 2012;118:3920–3927.22614698
   PubMed Web of Science ®Google Scholar
• Bamias A, Deliveliotis C, Karayiannis A, et al. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results. Eur Urol. 2004;46:344–350.15306106
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889–1894.24821883
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61:1229–1238.22189383
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115:4104–4109.19517476
   PubMed Web of Science ®Google Scholar
• Lavery HJ, Stensland KD, Niegisch G, Albers P, Droller MJ. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. J Urol. 2014;191:898–906.24300483
   PubMed Web of Science ®Google Scholar
• Weight CJ, Garcia JA, Hansel DE, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. A contemporary series. Cancer. 2009;115(4):792–799.19127557
   PubMed Web of Science ®Google Scholar
• Alva AS, Tallman CT, He C, et al. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer a multidisciplinary approach. Cancer. 2012;118:44–53.21598245
   PubMed Web of Science ®Google Scholar
• Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015;67(2):241–249.25257030
   PubMed Web of Science ®Google Scholar
• Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res. 2006;12:139–143.16397035
   PubMed Web of Science ®Google Scholar
• Lee CT, Madii R, Daignault S, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006;175:1262–1267.16515975
   PubMed Web of Science ®Google Scholar
• Liu D, Plimack ER, Hoffman-Censits J, et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2016;2(8):1094–1096.27310333
   PubMed Web of Science ®Google Scholar
• Pietzak EJ, Zabor EC, Bagrodia A, et al. Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur Urol. 2019;75(2):231–239.30290956
   PubMed Web of Science ®Google Scholar